Article Details
Retrieved on: 2021-01-02 06:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Morgan Stanley raised their target price on Insmed from $42.00 to $55.00 and gave the company an "overweight" rating in a research report on ...
Article found on: www.marketbeat.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here